2020
Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S, Kim K. Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis. Journal Of Clinical Oncology 2020, 38: e21061-e21061. DOI: 10.1200/jco.2020.38.15_suppl.e21061.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyIncremental cost-effectiveness ratioStage I non-small cell lung cancerOne-way sensitivity analysesCell lung cancerBody radiotherapyRecurrence riskLung cancerHealth benefitsStage I NSCLC patientsLong-term prospective trialsPerfect healthAnnual recurrence riskHealth care sector perspectiveShort-term complicationsSensitivity analysisLong-term surveillanceThermal ablationWeeks of lifeCost-effectiveness analysisCost-effectiveness ratioDeterministic sensitivity analysesMedicare billing dataMultiple sensitivity analyses
2016
Resection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy
Lushaj E, Julliard W, Bretl T, Badami A, Macke R, Blasberg J, Maloney J. Resection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy. Cancer Treatment And Research Communications 2016, 5: 22-25. DOI: 10.1016/j.ctrc.2015.12.002.Peer-Reviewed Original ResearchNon-small cell lung cancerIIIA non-small cell lung cancerStage IIIA non-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryStage IIIA patientsIIIA patientsStage IStage IIMultimodality therapySurvival rateMedian hospital lengthOverall survival rateResults Mean ageCell lung cancerPost-treatment survivalInitial therapyAdvanced diseaseHospital lengthNeoadjuvant radiationPerioperative morbidityPulmonary resectionThoracoscopic surgeryOptimal therapySurgical intervention
2011
Management of Early Stage Non–Small Cell Lung Cancer in High-Risk Patients
Donington JS, Blasberg JD. Management of Early Stage Non–Small Cell Lung Cancer in High-Risk Patients. Thoracic Surgery Clinics 2011, 22: 55-65. PMID: 22108689, DOI: 10.1016/j.thorsurg.2011.08.018.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerHigh-risk patientsCell lung cancerLung cancerStage I non-small cell lung cancerStage non-small cell lung cancerPeri-procedural morbidityOperable lung cancerType of resectionRefinement of indicationsAnatomic resectionMediastinal lymphSublobar resectionOncologic efficacyTreatment optionsPreferred treatmentResectionPatientsCancerTreatmentLobectomyLymphMorbidityMortality
2010
Sublobar Resection: A Movement from the Lung Cancer Study Group
Blasberg JD, Pass HI, Donington JS. Sublobar Resection: A Movement from the Lung Cancer Study Group. Journal Of Thoracic Oncology 2010, 5: 1583-1593. PMID: 20879185, DOI: 10.1097/jto.0b013e3181e77604.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSublobar resectionStage IA non-small cell lung cancerStage I non-small cell lung cancerMulti-institutional phase III trialLung Cancer Study GroupPostoperative lung functionSingle-institution trialLung cancer resectionCancer Study GroupHigh-risk patientsPhase III trialsEarly-stage diseaseInvasive surgical resectionCell lung cancerHigh-risk individualsMultislice computer tomographyRate of survivalPerioperative morbidityIII trialsSurgical resectionCancer resectionLung functionOncologic effectivenessRecurrence rate